VMAT2 Inhibitors in Neuropsychiatric Disorders.

abstract：:The circadian rhythm of pineal melatonin secretion, which is controlled by the suprachiasmatic nucleus (SCN), is reflective of mechanisms that are involved in the control of the sleep/wake cycle. Melatonin can influence sleep-promoting and sleep/wake rhythm-regulating actions through the specific activation of MT(1) (...

journal_title：CNS drugs

authors： Pandi-Perumal SR,Srinivasan V,Spence DW,Cardinali DP

更新日期：2007-01-01 00:00:00

abstract：SYNOPSIS:Mirtazapine is a tetracyclic antidepressant with a novel mechanism of action; it increases noradrenergic and serotonergic neurotransmission via blockade of central α2-adrenergic auto- and heteroreceptors. The increased release of serotonin (5-hydroxytryptamine; 5-HT) stimulates serotonin 5-HT1 receptors becaus...

journal_title：CNS drugs

authors： Davis R,Wilde MI

更新日期：1996-05-01 00:00:00

abstract：BACKGROUND:Cenobamate is a novel tetrazole-derived carbamate compound with a dual mechanism of action. This drug can enhance the inactivated state of voltage-gated sodium channels, preferentially inhibiting the persistent component of the sodium channel current, and acts as a positive allosteric modulator of GABAA rece...

journal_title：CNS drugs

authors： Lattanzi S,Trinka E,Zaccara G,Striano P,Del Giovane C,Silvestrini M,Brigo F

更新日期：2020-11-01 00:00:00

abstract：:Spinal cord injury (SCI) has a number of severe and disabling consequences, including chronic pain, and around 40% of patients develop persistent neuropathic pain. Pain following SCI has a detrimental impact on the patient's quality of life and is a major specific healthcare problem in its own right. Thus far, there i...

journal_title：CNS drugs

authors： Baastrup C,Finnerup NB

更新日期：2008-01-01 00:00:00

abstract：INTRODUCTION:The gabapentinoids pregabalin and gabapentin are being increasingly prescribed for a range of clinical conditions. Recently, although gabapentinoids at therapeutic dosages may present with low addictive liability levels, cases of misuse and rising numbers of related fatalities have been reported. OBJECTIV...

journal_title：CNS drugs

authors： Chiappini S,Schifano F

更新日期：2016-07-01 00:00:00

abstract：:Aripiprazole (Abilify(®)) is an atypical antipsychotic that is widely used in the treatment of psychiatric conditions. Unlike other currently available atypical antipsychotics that primarily have varying degrees of dopamine D2 receptor antagonism, aripiprazole is a partial agonist at D2 and serotonin 5-HT1A receptors,...

journal_title：CNS drugs

authors： McKeage K

更新日期：2014-02-01 00:00:00

abstract：:The neuronal ceroid lipofuscinoses comprise a group of neurodegenerative lysosomal storage disorders caused by mutations in at least 13 different genes and primarily affect the brain and the retina of children or young adults. The disorders are characterized by progressive neurological deterioration with dementia, epi...

journal_title：CNS drugs

authors： Kohlschütter A,Schulz A,Bartsch U,Storch S

更新日期：2019-04-01 00:00:00

abstract：:Evidence-based treatment approaches for generalized anxiety disorder (GAD) comprise psychotherapy, pharmacotherapy, or a combination of the two. First-line pharmacotherapy agents include selective serotonin reuptake inhibitors, selective serotonin-norepinephrine reuptake inhibitors, and, in certain European guidelines...

journal_title：CNS drugs

authors： Hershenberg R,Gros DF,Brawman-Mintzer O

更新日期：2014-06-01 00:00:00

abstract：:Mutations in the isocitrate dehydrogenase (IDH) 1 gene are commonly found in human glioma, with the majority of low-grade gliomas harboring a recurrent point mutation (IDH1 R132H). Mutant IDH reveals an altered enzymatic activity leading to the synthesis of 2-hydroxyglutarate, which has been implicated in epigenetic m...

journal_title：CNS drugs

authors： Karpel-Massler G,Nguyen TTT,Shang E,Siegelin MD

更新日期：2019-12-01 00:00:00

abstract：:Existing drug delivery methods have not led to a significant increase in survival for patients with malignant primary brain tumors. While the combination of conventional therapies consisting of surgery, radiotherapy, and chemotherapy has improved survival for some types of brain tumors (e.g., WNT medulloblastoma), oth...

journal_title：CNS drugs

authors： Haumann R,Videira JC,Kaspers GJL,van Vuurden DG,Hulleman E

更新日期：2020-11-01 00:00:00

abstract：:Anticonvulsant hypersensitivity syndrome (AHS) is a rare, but potentially fatal, adverse reaction that occurs in patients, including children, who are treated with anticonvulsants. During metabolism of the anticonvulsant, toxic arene-oxide compounds are produced. AHS is associated with both cutaneous and systemic symp...

journal_title：CNS drugs

authors： Verrotti A,Trotta D,Salladini C,Chiarelli F

更新日期：2002-01-01 00:00:00

abstract：:Major depressive disorder (MDD) is a chronic, recurrent mental disease that causes serious disability. Because currently available antidepressants have limited efficacy with respect to response and remission in patients with MDD, clinicians must choose the best available treatment interventions for patients who do not...

journal_title：CNS drugs

authors： Pae CU,Patkar AA

更新日期：2013-05-01 00:00:00

abstract：:Benzodiazepine hypnotic agents were the mainstream pharmacotherapy for insomnia from the 1960s to the 1980s, but their safety profile proved to be not quite as perfect as originally expected with regard to daytime performance and cognition, and above all the risk of dependence. These risks are substantially diminished...

journal_title：CNS drugs

authors： Lee YJ

更新日期：2004-01-01 00:00:00

abstract：:Dravet syndrome (DS) is a medically refractory epilepsy that onsets in the first year of life with prolonged seizures, often triggered by fever. Over time, patients develop other seizure types (myoclonic, atypical absences, drops), intellectual disability, crouch gait and other co-morbidities (sleep problems, autonomi...

journal_title：CNS drugs

authors： Knupp KG,Wirrell EC

更新日期：2018-04-01 00:00:00

abstract：:Premature mortality due to cardiovascular disease in those with schizophrenia is the largest lifespan disparity in the US and is growing; adults in the US with schizophrenia die, on average, 28 years earlier than those in the general population. The rate of smoking prevalence among individuals with schizophrenia is es...

journal_title：CNS drugs

authors： Cather C,Pachas GN,Cieslak KM,Evins AE

更新日期：2017-06-01 00:00:00

abstract：:Narcolepsy type 1 and narcolepsy type 2 are central disorders of hypersomnolence. Narcolepsy type 1 is characterized by excessive daytime sleepiness and cataplexy and is associated with hypocretin-1 deficiency. On the other hand, in narcolepsy type 2, cerebrospinal fluid hypocretin-1 levels are normal and cataplexy ab...

journal_title：CNS drugs

authors： Barateau L,Lopez R,Dauvilliers Y

更新日期：2016-05-01 00:00:00

abstract：:Treatment of pediatric migraine remains an unmet medical need. There continues to be a paucity of pediatric randomized controlled trials for the treatment of migraine, both in the acute and preventive settings. Pediatric studies are often complicated by high placebo-response rates and much of our current practice is b...

journal_title：CNS drugs

authors： Kacperski J,Hershey AD

更新日期：2016-09-01 00:00:00

abstract：OBJECTIVE:To collect descriptive data on the treatment of Alzheimer's disease with galantamine under naturalistic conditions. STUDY DESIGN:This was a prospective, open-label, observational study. PATIENTS:Subjects (n = 345) with mild to moderately severe dementia of the Alzheimer's type were recruited from 48 hospita...

journal_title：CNS drugs

authors： Brodaty H,Woodward M,Boundy K,Barnes N,Allen G,NATURE Investigators.

更新日期：2006-01-01 00:00:00

abstract：:Oral fingolimod (Gilenya™), a sphingosine 1-phosphate (S1P) receptor agonist, is the first oral agent and the first in a novel class of disease-modifying therapies (DMTs) to be approved for use in the US for the treatment of relapsing forms of multiple sclerosis (MS). In the EU, fingolimod is approved for use as a sin...

journal_title：CNS drugs

authors： Scott LJ

更新日期：2011-08-01 00:00:00

abstract：:Biopharmaceuticals can induce antibodies, which interact with and neutralize the therapeutic effect of such drugs and are therefore termed neutralizing antibodies (NAbs). In the treatment of multiple sclerosis, NAbs against interferon (IFN)-beta and natalizumab have been recognized. The prevalence of NAbs against diff...

journal_title：CNS drugs

authors： Deisenhammer F

更新日期：2009-01-01 00:00:00

abstract：:Treatment-resistant depression (TRD) presents major challenges for both patients and clinicians. There is no universally accepted definition of TRD, but results from the US National Institute of Mental Health's (NIMH) STAR*D (Sequenced Treatment Alternatives to Relieve Depression) programme indicate that after the fai...

journal_title：CNS drugs

authors： Shelton RC,Osuntokun O,Heinloth AN,Corya SA

更新日期：2010-02-01 00:00:00

abstract：:Bipolar depression is the predominant abnormal mood state in bipolar disorder. However, despite the key pertinence of this phase of the condition, the focus of research and indeed of clinical interest in the management of bipolar disorder has been mainly on mania. Bipolar depression has been largely neglected, and ear...

journal_title：CNS drugs

authors： Malhi GS,Mitchell PB,Salim S

更新日期：2003-01-01 00:00:00

abstract：:The coronavirus 2019 (COVID-19) pandemic is expected to linger. Decisions regarding initiation or continuation of disease-modifying therapy for multiple sclerosis have to consider the potential relevance to the pandemic. Understanding the mechanism of action and the possible idiosyncratic effects of each therapeutic a...

journal_title：CNS drugs

authors： Zheng C,Kar I,Chen CK,Sau C,Woodson S,Serra A,Abboud H

更新日期：2020-09-01 00:00:00

abstract：:L-Dopa-induced dyskinesias (LID) are the most common adverse effects of long-term dopaminergic therapy in Parkinson's disease (PD). However, the exact mechanisms underlying dyskinesia are still unclear. For a long time, nigrostriatal degeneration and pulsatile stimulation of striatal postsynaptic receptors have been h...

journal_title：CNS drugs

authors： Schaeffer E,Pilotto A,Berg D

更新日期：2014-12-01 00:00:00

abstract：:Multiple sclerosis (MS) is a demyelinating disease of the central nervous system that is pathologically characterized by inflammatory demyelination and neurodegeneration. Axonal damage, along with neuronal loss, occurs from disease onset and may lead to progressive and permanent disability. In contrast with the inflam...

journal_title：CNS drugs

authors： Maghzi AH,Minagar A,Waubant E

更新日期：2013-10-01 00:00:00

abstract：:Oxcarbazepine (Trileptal, Timox) is structurally related to carbamazepine and has anticonvulsant activity. Studies suggest that the anticonvulsant activity of oxcarbazepine is mediated via the blocking of neuronal ion channels. In patients aged <18 years, the efficacy of oxcarbazepine monotherapy was similar to that o...

journal_title：CNS drugs

authors： Bang LM,Goa KL

更新日期：2004-01-01 00:00:00

abstract：:Progress in finding a better alternative to alteplase has been slow. Tenecteplase and desmoteplase have better pharmacological profiles compared with alteplase, but definite clinical evidence of their superiority is lacking. The two major phase III studies that have tested the efficacy and safety of desmoteplase in is...

journal_title：CNS drugs

authors： Logallo N,Kvistad CE,Nacu A,Thomassen L

更新日期：2016-02-01 00:00:00

abstract：:Assessing the risk of stroke in persons with migraine is complicated by the intricate relationship between these two conditions. Both migraine and stroke are common and co-morbidity may, in some cases, be coincidental. Given the overlap of clinical symptoms in stroke and migraine, each condition may also mimic the oth...

journal_title：CNS drugs

authors： Tietjen GE

更新日期：2005-01-01 00:00:00

abstract：:Pregabalin, the pharmacologically active S-enantiomer of 3-aminomethyl-5-methylhexanoic acid, possesses anticonvulsant activity. Pregabalin binds with high affinity and specificity to voltage-gated calcium channel alpha(2)-delta proteins. The putative mechanism of action of the drug is reduced excitatory neurotransmit...

journal_title：CNS drugs

authors： Warner G,Figgitt DP

更新日期：2005-01-01 00:00:00

abstract：:Loxapine is a well-established, first-generation antipsychotic agent. Loxapine inhalation powder (Adasuve(®)) was recently approved in the USA and the EU for use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia. Inhaled loxapine is delivered by a hand-held, single-dose, single-use...

journal_title：CNS drugs

authors： Keating GM

更新日期：2013-06-01 00:00:00